Royalty Pharma plc Other Comprehensive Income (Loss), Net of Tax
Royalty Pharma plc (RPRX) reported Other Comprehensive Income (Loss), Net of Tax of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2025-02-12
- Royalty Pharma plc other comprehensive income (loss), net of tax for the quarter ending 2023-12-31 was $0.00.
- Royalty Pharma plc other comprehensive income (loss), net of tax for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Royalty Pharma plc other comprehensive income (loss), net of tax for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Royalty Pharma plc other comprehensive income (loss), net of tax for the quarter ending 2023-03-31 was $0.00.
- Royalty Pharma plc other comprehensive income (loss), net of tax for fiscal 2024 was $0.00.
- Royalty Pharma plc other comprehensive income (loss), net of tax for fiscal 2023 was $0.00.
- Royalty Pharma plc other comprehensive income (loss), net of tax for fiscal 2022 was -$29.43M.
- Royalty Pharma plc other comprehensive income (loss), net of tax for fiscal 2021 was -$39.30M, a 158.97% decline from fiscal 2020.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-12 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $0.00 derived: sum of 2 quarters · filed 2025-02-12 | $0.00 derived: sum of 3 quarters · filed 2025-02-12 | $0.00 10-K · filed 2025-02-12 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | -$29.38M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | -$29.38M derived: sum of 3 quarters · filed 2025-02-12 | -$23.44M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | -$29.38M derived: sum of 2 quarters · filed 2025-02-12 | -$23.44M derived: sum of 3 quarters · filed 2025-02-12 | -$22.10M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | -$29.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$23.44M derived: sum of 2 quarters · filed 2025-02-12 | -$22.10M derived: sum of 3 quarters · filed 2025-02-12 | -$29.43M 10-K · filed 2025-02-12 |
| 2022-09-30 | $5.94M 10-Q · filed 2023-11-08 | $7.28M derived: sum of 2 quarters · filed 2023-11-08 | -$53.00K 10-Q · filed 2023-11-08 | -$7.38M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $1.34M 10-Q · filed 2023-08-08 | -$5.99M 10-Q · filed 2023-08-08 | -$13.32M derived: sum of 3 quarters · filed 2024-02-15 | -$27.65M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | -$7.33M 10-Q · filed 2023-05-09 | -$14.65M derived: sum of 2 quarters · filed 2024-02-15 | -$28.98M derived: sum of 3 quarters · filed 2024-02-15 | -$36.26M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -$7.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$21.66M derived: sum of 2 quarters · filed 2024-02-15 | -$28.93M derived: sum of 3 quarters · filed 2024-02-15 | -$39.30M 10-K · filed 2024-02-15 |
| 2021-09-30 | -$14.33M 10-Q · filed 2022-11-08 | -$21.61M derived: sum of 2 quarters · filed 2022-11-08 | -$31.97M 10-Q · filed 2022-11-08 | -$36.65M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | -$7.27M 10-Q · filed 2022-08-04 | -$17.64M 10-Q · filed 2022-08-04 | -$22.32M derived: sum of 3 quarters · filed 2023-02-15 | -$14.74M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | -$10.37M 10-Q · filed 2022-05-05 | -$15.04M derived: sum of 2 quarters · filed 2023-02-15 | -$7.47M derived: sum of 3 quarters · filed 2023-02-15 | -$522.00K derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | -$4.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $2.90M derived: sum of 2 quarters · filed 2023-02-15 | $9.84M derived: sum of 3 quarters · filed 2023-02-15 | $66.64M 10-K · filed 2023-02-15 |
| 2020-09-30 | $7.57M 10-Q · filed 2021-11-10 | $14.52M derived: sum of 2 quarters · filed 2021-11-10 | $71.31M 10-Q · filed 2021-11-10 | $78.81M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $6.95M 10-Q · filed 2021-08-11 | $63.74M 10-Q · filed 2021-08-11 | $71.24M derived: sum of 3 quarters · filed 2022-02-15 | $69.96M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $56.79M 10-Q · filed 2021-05-11 | $64.29M derived: sum of 2 quarters · filed 2022-02-15 | $63.01M derived: sum of 3 quarters · filed 2022-02-15 | $67.55M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $7.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $6.22M derived: sum of 2 quarters · filed 2022-02-15 | $10.76M derived: sum of 3 quarters · filed 2022-02-15 | $12.35M 10-K · filed 2022-02-15 |
| 2019-09-30 | -$1.28M 10-Q · filed 2020-11-12 | $3.26M derived: sum of 2 quarters · filed 2020-11-12 | $4.85M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $4.54M 10-Q · filed 2020-08-12 | $6.13M 10-Q · filed 2020-08-12 | ||
| 2018-12-31 | -$394.50M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |